Quetiapine

Introduction Overview

Generic Name

quetiapine

Brand Name

Seroquel, Seroquel XR

Dosage Form

oral tablet (immediate release and extended release)

Drug Class

Atypical antipsychotics

Pharmacokinetics

Absorption:
Quetiapine is well absorbed after oral administration, with peak plasma concentrations typically reached within 1.5 hours for immediate-release formulations and approximately 6 hours for extended-release (XR) tablets. The absolute bioavailability is not precisely defined due to extensive first-pass metabolism. Food does not significantly affect the extent of absorption, allowing administration with or without meals; however, consistent administration with regard to meals is recommended for maintaining stable plasma concentrations. XR tablets provide a sustained release, facilitating once-daily dosing and smoother plasma concentration profiles compared to immediate-release forms.

Distribution:
Quetiapine exhibits an extensive distribution throughout the body, with a volume of distribution ranging from approximately 5 to 14 L/kg, indicating extensive tissue binding. It is approximately 83% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein. Quetiapine crosses the blood-brain barrier efficiently, which is critical for its central nervous system activity. It also crosses the placenta and is found in breast milk, necessitating caution during pregnancy and lactation. The distribution pattern supports its efficacy in treating central psychiatric disorders.

Metabolism:
Quetiapine undergoes extensive hepatic metabolism primarily via the cytochrome P450 isoenzyme CYP3A4. The main metabolic pathway involves oxidation and sulfation leading to several inactive metabolites. The principal active metabolite, norquetiapine (N-desalkyl quetiapine), contributes to the pharmacological profile, particularly regarding antidepressant effects. Factors affecting CYP3A4 activity, such as concomitant use of inhibitors or inducers, can alter quetiapine plasma levels significantly and require clinical monitoring. The metabolism is so extensive that less than 1% of unchanged drug is excreted in urine or feces.

Elimination:
The elimination half-life of quetiapine averages 6 to 7 hours for immediate-release formulations and about 6 hours for XR tablets, allowing for once or twice daily dosing regimens. Quetiapine and its metabolites are primarily eliminated via renal (urine) and fecal routes, mostly as metabolites rather than unchanged drug. Clearance can be influenced by hepatic function; thus, dose adjustments may be necessary in patients with hepatic impairment. The pharmacokinetic profile supports flexible dosing and titration schedules in clinical practice.

Dosage Forms

Available Dosage Forms:
Quetiapine is available as immediate-release oral tablets and extended-release (XR) oral tablets.
- Immediate-release oral tablets are available in the following strengths: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, and 400 mg.
- Extended-release (XR) oral tablets come in strengths of 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg.

Dosages for Adults and Adolescents:
The dosage of quetiapine varies according to the indication. For schizophrenia in adults, initial doses typically start at 25 mg twice daily, titrated over several days to 300-400 mg per day, administered in two or three divided doses for immediate-release or once daily for XR formulations. In bipolar disorder, both manic and depressive episodes, doses are similarly initiated and titrated, with maintenance doses usually ranging from 400 mg to 800 mg per day. For adolescents aged 13 and older, dosing is similarly titrated, often starting lower and adjusted based on clinical response and tolerability. The XR formulation may be preferential for once-daily dosing to improve adherence.

Specific Patient Populations:
In elderly patients or those with hepatic impairment, dose adjustments are important due to altered metabolism and increased sensitivity to adverse effects. Initiate therapy at lower doses with slower titration. For children with bipolar disorder aged 10 and older, quetiapine XR is approved for manic episodes, with dosing carefully titrated from low starting doses. Renal impairment does not necessitate dose adjustment but warrants close monitoring. Use caution during pregnancy and lactation, weighing risks and benefits. Overall, individualization of dosing is essential based on patient's clinical condition, comorbidities, and concomitant medications.

Mechanism Of Action

Quetiapine is an atypical antipsychotic that exerts its therapeutic effects primarily through antagonism of multiple neurotransmitter receptors in the brain with varying affinities. Unlike typical antipsychotics, which predominantly block dopamine D2 receptors, quetiapine has a broader receptor profile that contributes to its clinical efficacy and reduced extrapyramidal side effects.

At the molecular level, quetiapine exhibits antagonistic activity at serotonin 5-HT2A and dopamine D2 receptors, with a higher affinity for 5-HT2A. This serotonin-dopamine receptor blockade modulates dopaminergic and serotonergic neurotransmission, ameliorating psychotic symptoms while minimizing motor side effects. Additionally, quetiapine and its active metabolite norquetiapine exhibit partial agonism at 5-HT1A receptors, which may contribute to anxiolytic and antidepressant effects.

Furthermore, quetiapine antagonizes histamine H1 and adrenergic α1 and α2 receptors, which contributes to its sedative properties and hypotensive effects. The antagonism at histaminergic receptors is implicated in its sedating and weight gain side effects, while α1 blockade may cause orthostatic hypotension. The engagement of multiple receptor pathways explains quetiapine’s utility in a range of psychiatric conditions, including schizophrenia, bipolar disorder, and as adjunctive treatment in major depressive disorder.

Clinical studies support quetiapine’s efficacy correlating with its multi-receptor pharmacodynamics: the balanced blockade of dopamine and serotonin receptors results in improvement of positive and negative symptoms of schizophrenia, stabilization of mood in bipolar disorder, and augmentation of antidepressants in major depression. Comparative studies show that quetiapine’s receptor activity profile leads to less risk of extrapyramidal symptoms and tardive dyskinesia compared to typical antipsychotics. Ongoing research continues to explore norquetiapine’s role in neuroplasticity and neuroprotection mechanisms.

Pharmacological Actions

Atypical antipsychotic activity via dopamine D2 and serotonin 5-HT2A receptor antagonism.
Partial agonist activity at serotonin 5-HT1A receptors contributing to anxiolytic and antidepressant effects.
Antagonism of histamine H1 receptors resulting in sedation and weight gain.
Blockade of adrenergic α1 and α2 receptors leading to hypotension and reflex tachycardia.
Mood stabilization effects beneficial in bipolar disorder, including manic and depressive episodes.
Modulation of multiple neurotransmitter systems including serotonin, dopamine, histamine, and norepinephrine.
Reduction of psychotic symptoms such as hallucinations, delusions, and thought disorder.
Improvement of depressive symptoms when used adjunctively with antidepressants.
Lower propensity for extrapyramidal symptoms compared to typical antipsychotics.
Neuroprotective actions potentially mediated by active metabolite norquetiapine.
Anxiolytic properties supporting use in generalized anxiety and mood disorders.

Therapeutic Or Clinical Uses

Treatment of schizophrenia in adults and adolescents aged 13 years and older.
Management of manic and mixed episodes of bipolar disorder in adults and children 10 years and older (XR formulation).
Bipolar depression and maintenance therapy to prevent mood episode recurrence.
Adjunctive treatment in major depressive disorder in adults.
Management of psychotic symptoms associated with mood disorders.
Off-label uses including generalized anxiety disorder and borderline personality disorder (with clinical discretion).
Symptom control in schizophrenia spectrum disorders, including positive and negative symptoms.
Treatment of agitation and behavioral disturbances in psychiatric conditions.
Sleep improvement in certain psychiatric populations, although not primarily indicated as a hypnotic.
Alternative to typical antipsychotics for patients who experience extrapyramidal side effects.
Use in treatment programs involving schizophrenia and bipolar disorder in pediatric and adolescent populations.

Side Or Adverse Effects

Dizziness, drowsiness, and sedation are among the most common side effects.
Weight gain and increased appetite frequently occur during therapy.
Orthostatic hypotension due to α1 adrenergic receptor blockade leading to dizziness and risk of falls.
Extrapyramidal symptoms including tremor, dystonia, and akathisia, though less frequent than typical antipsychotics.
Metabolic disturbances such as hyperglycemia, diabetes mellitus onset or worsening, and lipid abnormalities.
Elevated prolactin levels causing breast swelling, tenderness, nipple discharge, and sexual dysfunction.
Potential for tardive dyskinesia and neuroleptic malignant syndrome, especially with long-term or high-dose use.
Increased risk of infections related to leukopenia or neutropenia, including fever, sore throat, and mouth sores.
Gastrointestinal disturbances such as nausea, vomiting, constipation, and abdominal pain.
Cardiac effects including tachycardia, bradycardia, and rare cases of QT interval prolongation.
Dry mouth, nasal congestion, and blurred vision due to anticholinergic effects.
Sleep disturbances such as insomnia or abnormal dreams.
Risk of seizures, particularly in patients with predisposing conditions.
Endocrine effects including hypothyroidism and weight gain.
Serious allergic reactions including angioedema and anaphylaxis, though rare.

Precautions

Monitor for new or worsening mood changes, suicidal ideation, or behavioral changes, especially in young people and adolescents.
Use caution in patients with a history of cardiovascular disease, including QT prolongation, arrhythmias, or recent myocardial infarction.
Regularly monitor metabolic parameters including blood glucose, lipid profile, and weight to detect metabolic syndrome.
Be vigilant for signs of neuroleptic malignant syndrome, a potentially life-threatening condition.
Assess for extrapyramidal symptoms and tardive dyskinesia during long-term therapy.
Screen for leukopenia or neutropenia; monitor complete blood counts especially in patients with infection risk.
Use cautiously in patients with pre-existing liver impairment; dose adjustment may be necessary.
Avoid abrupt discontinuation to prevent withdrawal symptoms and relapse of psychiatric symptoms.
Consider risk-benefit carefully in elderly patients, particularly those with dementia-related psychosis due to increased mortality risk.
Advise patients to rise slowly from sitting or lying positions to reduce risk of orthostatic hypotension.
Inform patients about the potential for sedation; caution advised before engaging in hazardous activities like driving.
Caution in patients with history of seizures as quetiapine may lower seizure threshold.
Evaluate thyroid function periodically as quetiapine may cause hypothyroidism.
Pregnancy should be planned carefully with healthcare provider consultation due to potential risks to fetus and newborn.
Advise patients on importance of adherence and regular follow-up to monitor efficacy and safety.

Warnings

Increased risk of death in older adults with dementia-related psychosis treated with antipsychotic drugs.
Potential for suicidal ideation and behavior in children, adolescents, and young adults, especially during early treatment phases.
Risk of tardive dyskinesia, a potentially irreversible movement disorder, especially with prolonged use or high doses.
Possibility of neuroleptic malignant syndrome characterized by hyperthermia, muscle rigidity, autonomic instability, and altered mental status.
May cause severe orthostatic hypotension, increasing fall risk, particularly in elderly or debilitated patients.
Potential for metabolic side effects including hyperglycemia, diabetes, and dyslipidemia; monitoring is essential.
Use in late pregnancy may cause extrapyramidal and withdrawal symptoms in neonates.
May prolong the QT interval, increasing risk for torsades de pointes in predisposed individuals.
Can cause leukopenia, neutropenia, and agranulocytosis; infections should be promptly evaluated.
Sedation and cognitive impairment may increase risk when driving or operating machinery.
Avoid concurrent use with other QT-prolonging drugs to prevent additive effects.
Abrupt discontinuation can precipitate withdrawal symptoms and symptom relapse.
Caution advised in patients with hypotension or dehydration due to risk of exacerbation.
Potential for hypersensitivity reactions, including rare reports of anaphylaxis.
May impair thermoregulation, increasing risk of hyperthermia or heat stroke in hot environments.

Contraindication

Known hypersensitivity or allergy to quetiapine or any component of the formulation.
Use with caution in combination with other central nervous system depressants without medical supervision.
Contraindicated in patients with a history of neuroleptic malignant syndrome related to quetiapine or other antipsychotics.
Use is not recommended in elderly patients with dementia-related psychosis due to increased mortality risk.
Avoid use in patients with uncontrolled narrow-angle glaucoma due to anticholinergic effects.
Patients with a history of severe cardiac arrhythmias or prolonged QT interval should not use quetiapine without careful risk assessment.
Contraindicated in patients with known severe hepatic impairment where drug metabolism is compromised.
Not indicated for treatment of dementia-related behavioral disturbances due to risk-benefit considerations.
Should not be administered to patients contraindicated to any of the inactive tablet ingredients causing allergic reactions.
Use contraindicated in patients with untreated electrolyte abnormalities such as hypokalemia or hypomagnesemia.
Avoid use in patients with seizure disorders unless benefits outweigh risks and on close monitoring.
Contraindicated in combination with strong CYP3A4 inhibitors unless dose adjustment and close monitoring are implemented.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase quetiapine plasma levels, enhancing toxicity risk.
CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) may reduce quetiapine efficacy by lowering plasma concentrations.
Concurrent use with other CNS depressants, including alcohol, benzodiazepines, and opioids, may increase sedation and respiratory depression.
Drugs that prolong QT interval (e.g., certain antiarrhythmics, antimalarials) can synergistically increase arrhythmia risk when combined with quetiapine.
Beta-blockers or antihypertensives combined with quetiapine may exacerbate hypotensive effects.
Use with medications for Parkinson’s disease (levodopa, dopamine agonists) may have antagonistic effects on symptom control.
Concomitant use with anticholinergic drugs may enhance anticholinergic adverse effects, such as constipation and urinary retention.
Serotonergic agents used simultaneously could increase risk of serotonin syndrome, although rare with quetiapine.
Use with inhibitors or inducers of P-glycoprotein may affect quetiapine absorption and distribution.
Interaction with cold or allergy medications containing diphenhydramine can increase sedation and anticholinergic burden.
Asthma bronchodilators may augment cardiovascular side effects such as tachycardia when used with quetiapine.
Drugs for motion sickness, irritable bowel syndrome, or overactive bladder may increase anticholinergic side effects when used concomitantly.
Concomitant use with certain cancer chemotherapeutic agents may compete for metabolic pathways, altering quetiapine levels.
Interactions with HIV protease inhibitors or non-nucleoside reverse transcriptase inhibitors require monitoring due to effects on CYP3A4 metabolism.
Laboratory urine drug screens may yield false positive results due to quetiapine; inform laboratory and clinical staff.

Preparations Of The Drug

Immediate-release oral tablets: available in 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, and 400 mg strengths, used for multiple daily dosing.
Extended-release (XR) oral tablets: available in 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg strengths for once-daily administration.
Tablets contain inactive ingredients including povidone, dibasic dicalcium phosphate dihydrate, microcrystalline cellulose, sodium starch glycolate, lactose monohydrate, magnesium stearate, hypromellose, polyethylene glycol, and titanium dioxide.
Colorants in tablets include yellow and red ferric oxide depending on the dosage strength.
Film coating for XR tablets contains hypromellose, polyethylene glycol 400, titanium dioxide, and iron oxides for specific strengths.
Manufactured by AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Available commercially under brand names Seroquel and Seroquel XR with approved labeling.
Packaging includes blister packs and bottles tailored for outpatient and inpatient use.
Storage recommended at room temperature away from moisture and heat to maintain drug stability.
Prescriptions typically specify formulation choice depending on clinical scenario and patient adherence considerations.
Patient information leaflets accompany preparations detailing dosing, side effects, and precautions.
Extended release tablets are designed to provide steady plasma concentrations and improve tolerability.
Formulations are designed to avoid crushing or chewing to maintain pharmacokinetic integrity.
Seroquel XR tablets provide an alternative for patients requiring simplified dosing regimens.
Available internationally with formulation equivalence adhering to regulatory approval standards.